High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Tyrosine kinase inhibitors (TKIs), despite their efficacy as anticancer therapeutics, are associated with cardiovascular side effects ranging from induced arrhythmias to heart failure. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling. With these data, we generated a "cardiac safety index" to reflect the cardiotoxicities of existing TKIs. TKIs with low cardiac safety indices exhibit cardiotoxicity in patients. We also derived endothelial cells (hiPSC-ECs) and cardiac fibroblasts (hiPSC-CFs) to examine cell type-specific cardiotoxicities. Using high-throughput screening, we determined that vascular endothelial growth factor receptor 2 (VEGFR2)/platelet-derived growth factor receptor (PDGFR)-inhibiting TKIs caused cardiotoxicity in hiPSC-CMs, hiPSC-ECs, and hiPSC-CFs. With phosphoprotein analysis, we determined that VEGFR2/PDGFR-inhibiting TKIs led to a compensatory increase in cardioprotective insulin and insulin-like growth factor (IGF) signaling in hiPSC-CMs. Up-regulating cardioprotective signaling with exogenous insulin or IGF1 improved hiPSC-CM viability during cotreatment with cardiotoxic VEGFR2/PDGFR-inhibiting TKIs. Thus, hiPSC-CMs can be used to screen for cardiovascular toxicities associated with anticancer TKIs, and the results correlate with clinical phenotypes. This approach provides unexpected insights, as illustrated by our finding that toxicity can be alleviated via cardioprotective insulin/IGF signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“they generated a “cardiac safety index” to reflect the safety of existing tyrosine kinase inhibitors [23].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Sharma et al., 2017 performed a high-throughput toxicity screen assessing the cardiotoxicity of small molecule tyrosine kinase inhibitors.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606 · cited 5×
“Chemically defined differentiation of hiPSC-CMs The hiPSCs were differentiated into hiPSC-CMs using a chemically defined protocol and maintained in medium supplemented with human albumin and ascorbic acid (8).”
BackgroundMethodInfluentialSelf-citationDemetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · cited 1×
“This is reasonable because sorafenib and regorafenib (also known as fluoro-sorafenib) have similar molecular structures (24).”
BackgroundCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275 · cited 1×
“However, some TKIs are linked to severe cardiotoxicities including heart failure, reduced left ventricular ejection fraction, myocardial infarction, or arrhythmias (2, 3).”
BackgroundPatient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Cited by
Items 101–200 of 442
Tang, X., Wang, Z., Hu, S., & Zhou, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071313 · Cited by 40
Differentiation and Contractile Analysis of GFP‐Sarcomere Reporter hiPSC‐Cardiomyocytes
Sharma, A., Toepfer, C. N., Schmid, M., Garfinkel, A. C., & Seidman, C. E. (2018) · Current Protocols in Human Genetics · doi:10.1002/cphg.53 · Cited by 43
“The advent of hiPSC-CM technology has also allowed screening of drugs for cardiovascular efficacy and toxicity on a patient-specific level, something that was not possible previously due to a scarcity of human cardiac tissue for pharmacological testing (Sharma et al., 2017).”
BackgroundSelf-citationMozneb, M., Jenkins, A., Sances, S., Pohlman, S., Workman, M. J., West, D., Ondatje, B. N., El‐Ghazawi, K., Woodbury, A., Garcia, V. J., et al. (2024) · Lab on a Chip · doi:10.1039/d3lc00745f · Cited by 43
Self-citationAutophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities
Li, M., Russo, M., Pirozzi, F., Tocchetti, C. G., & Ghigo, A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.06.007 · Cited by 39
Lam, C. K., & Wu, J. C. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314695 · Cited by 38
Self-citationPopulation-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons
Huang, C. Y., Nicholson, M. W., Wang, J. Y., Ting, C. Y., Tsai, M. H., Cheng, Y. C., Liu, C. L., Chan, D. Z. H., Lee, Y. C., Hsu, C. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110643 · Cited by 36
Self-citationShaw, P., Bhowmik, A. D., Pillai, M. S. G., Robbins, N., Dwivedi, S. K. D., & Rao, G. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217750 · Cited by 42
Bozzi, A., Sayed, N., Matsa, E., Sass, G., Neofytou, E. A., Clemons, K. V., Corrêa‐Oliveira, R., Stevens, D. A., & Wu, J. C. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.04.017 · Cited by 36
“, 2014), thereby providing an ideal in vitro platform for modeling human cardiac diseases (Liu et al., 2018; Sayed et al., 2016; Sharma et al., 2017), drug screening (Liang et al.”
BackgroundSelf-citationThe Convergence of Stem Cell Technologies and Phenotypic Drug Discovery
Friese, A., Ursu, A., Hochheimer, A., Schöler, H. R., Waldmann, H., & Bruder, J. M. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.05.007 · Cited by 37
Brink, L., Grandela, C., Mummery, C. L., & Davis, R. P. (2020) · Stem Cells · doi:10.1002/stem.3110 · Cited by 38
Reprogramming: Emerging Strategies to Rejuvenate Aging Cells and Tissues
Alle, Q., Le Borgne, E., Milhavet, O., & Lemaitre, J.-M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083990 · Cited by 35
Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
Li, M., Li-ming, P., & Chen, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.966261 · Cited by 40
“using HiPSC-CMs, endothelial HiPSC-ECs, and cardiac fibroblasts HiPSC-CFs to detect the potention of 21 TKIs in inducing cardiotoxicity by high-throughput screening (95).”
MethodMechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity
Blair, C. A., & Pruitt, B. L. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901656 · Cited by 37
Maddah, M., Mandegar, M. A., Dame, K., Grafton, F., Loewke, K., & Ribeiro, A. J. S. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106895 · Cited by 38
Kwan, J. M., Oikonomou, E. K., Henry, M. L., & Sinusas, A. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.829553 · Cited by 36
“…proteins resulting in QT prolongation, all the way to exome sequencing to identify variants in cardiac injury pathway genes that protect against anthracycline-induced cardiotoxicity and dual transcriptomic and molecular machine learning to predict different types of cardiotoxic response (146– 150).”
BackgroundLi, Q., Zeng, K., Chen, Q., Han, C., Wang, X., Li, B., Miao, J., Zheng, B., Liu, J., Yuan, X., et al. (2024) · Autophagy · doi:10.1080/15548627.2024.2421699 · Cited by 38
“However, TKIs may upregulate VEGF pathway members to compensate for the loss of upstream KDR signaling, which, in turn, is involved in resistance to TKI treatment [10,11].”
Atlas of Exosomal microRNAs Secreted From Human iPSC-Derived Cardiac Cell Types
Chandy, M., Rhee, J., Ozen, M. O., Williams, D. R., Pepic, L., Liu, C., Zhang, H., Malisa, J., Lau, E., Demirci, U., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048364 · Cited by 34
“The exosomal miRNA profiles revealed that (1) let-7 miRNA precursors, which are suppressed by Lin28, are depleted in iPSC secretomes as expected; (2) only a subset of total cellular miRNAs are secreted (eg, both miR-155 and miR-143 are preferentially found in intracellular over exosomal pools in iPSCs); (3) a common c…”
BackgroundSelf-citationCheng, M., Yang, F., Liu, J., Yang, D., Zhang, S., Yu, Y., Jiang, S., & Dong, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.758010 · Cited by 35
“trial, they used human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to evaluate the 21 approved TKIs, and demonstrated that ponatinib is the most toxic (54).”
MethodThree-Dimensional Monolayer Stress Microscopy
Serrano, R., Aung, A., Yeh, Y., Varghese, S., Lasheras, J. C., & del Álamo, J. C. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.03.041 · Cited by 34
Self-citationSystems-Wide Approaches in Induced Pluripotent Stem Cell Models
Lau, E., Paik, D. T., & Wu, J. C. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013046 · Cited by 34
“Development 142(18):3231–38 [PubMed: 26209647] Lau et al.”
Self-citationShim, J. V., Chun, B., van Hasselt, J. G. C., Birtwistle, M. R., Saucerman, J. J., & Sobie, E. A. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00651 · Cited by 33
“By integrating the results with literature-reported TKI serum levels in patients, the authors developed a novel cardiac safety index for TKIs (Sharma et al., 2017).”
BackgroundResultInfluentialSchneider, C., Wallner, M., Kolesnik, E., Herbst, V., Mächler, H., Pichler, M., von Lewinski, D., Sedej, S., & Rainer, P. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-23630-w · Cited by 32
Machine Learning Techniques to Classify Healthy and Diseased Cardiomyocytes by Contractility Profile
Teles, D., Kim, Y., Ronaldson-Bouchard, K., & Vunjak‐Novakovic, G. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00418 · Cited by 33
The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs
Hrynchak, I., Sousa, E., Pinto, M. M. M., & Costa, V. M. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1316285 · Cited by 36
“…receptor) and an up-regulation in the expression of VEGF ligands led the authors to hypothesize that hiPSC-CMs may compensate for VEGFR2 signaling loss by upregulating auxiliary VEGFR expression, thus facilitating VEGF signaling in the absence of VEGFR2 kinase activity (Sharma et al., 2017).”
BackgroundMethodYe, D., Bao, Z., Yang, Y. P., Han, Z., Yu, Y., Xu, Z., Ma, W., Yuan, Y., Zhang, L., Xu, Y., et al. (2020) · Toxicology · doi:10.1016/j.tox.2020.152422 · Cited by 31
Primer on Biomarker Discovery in Cardio-Oncology
Rhee, J., Ky, B., Armenian, S. H., Yancy, C. W., & Wu, J. C. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.07.006 · Cited by 33
“Transcriptomic profiling of drug-treated iPSC-derived cardiac cells revealed distinct expression patterns and mechanistic insights for (9,10) tyrosine kinase inhibitor- (11), and trastuzumab-related cardiotoxicity (12).”
BackgroundSelf-citationOvics, P., Regev, D., Baskin, P., Davidor, M., Shemer, Y., Neeman-Egozi, S., Ben‐Haim, Y., & Binah, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197320 · Cited by 36
“[63] studied the cardiotoxic effects of 21 different TKIs in iPSC-CMs generated from patients receiving cancer treatment and healthy individuals.”
BackgroundGrabowska, M. E., Chun, B., Moya, R., & Saucerman, J. J. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.02.014 · Cited by 34
Deciphering pathogenicity of variants of uncertain significance with CRISPR-edited iPSCs
Guo, H., Liu, L., Nishiga, M., Cong, L., & Wu, J. C. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.08.009 · Cited by 33
Self-citationSong, C., Li, D., Zhang, J., & Zhao, X. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115852 · Cited by 31
4D Thermo-Responsive Smart hiPSC-CM Cardiac Construct for Myocardial Cell Therapy
Hann, S.-Y., Cui, H., Esworthy, T. J., & Zhang, L. G. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s402855 · Cited by 30
Liu, Z., Wang, H., Hou, G., Cao, H., Zhao, Y., & Yang, B. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28194 · Cited by 30
Ramachandra, C. J. A., Chua, J., Cong, S., Ja, K. P. M. M., SHIM, W. S. N., Wu, J. C., & Hausenloy, D. J. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa125 · Cited by 33
Self-citationActivation of PDGFRA signaling contributes to filamin C–related arrhythmogenic cardiomyopathy
Chen, S. N., Lam, C. K., Wan, Y., Gao, S., Malak, O. A., Zhao, S. R., Lombardi, R., Ambardekar, A. V., Bristow, M. R., Cleveland, J. C., et al. (2022) · Science Advances · doi:10.1126/sciadv.abk0052 · Cited by 34
Self-citationSelvakumar, D., Reyes, L., & Chong, J. J. H. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01666-9 · Cited by 30
Zhu, K., Bao, X., Wang, Y., Lu, T., & Zhang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113970 · Cited by 31
CCL2-mediated endothelial injury drives cardiac dysfunction in long COVID
Thomas, D., Noishiki, C., Gaddam, S., Wu, D., Manhas, A., Liu, Y., Tripathi, D., Kathale, N. D., Adkar, S. S., Garhyan, J., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00543-8 · Cited by 32
Self-citationSharma, A., Mücke, M. B., & Seidman, C. E. (2018) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.58 · Cited by 28
“Background Information Human iPSCs have attracted significant interest for their potential to accelerate in vitro disease modeling, high-throughput drug screening, and potentially clinical cell therapy (Sharma et al., 2017; Sharma et al., 2014; Sharma et al., 2013).”
BackgroundSelf-citationhiPSCs in cardio-oncology: deciphering the genomics
Pinheiro, E. A., Fetterman, K. A., & Burridge, P. W. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz018 · Cited by 29
“triphosphate (ATP) detection assay, a luminescence assay that lyses cells, inhibits cellular ATPases and uses luciferin and luciferase to generate light.(58,68,74,81,91,94,95) ATP measurement is a widely accepted surrogate for viability and linearly correlates with cellular plating density; however,”
BackgroundMethodInfluentialSelf-citationHuang, J., Feng, Q., Wang, L., & Zhou, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.655161 · Cited by 33
Yan, Y., Bejoy, J., Xia, J., Griffin, K., Guan, J., & Li, Y. (2019) · Scientific Reports · doi:10.1038/s41598-018-37686-1 · Cited by 27
Stack, J. P., Moslehi, J. J., Sayed, N., & Wu, J. C. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx811 · Cited by 27
“Targeting the VEGF pathways results in decreased capillary density, inducing myocardial hypoxia and HIF-1a stability and activation.6 Conditional HIF-1a overexpression in mice leads to a reversible cardiomyopathy characterized by impaired calcium handling and ventricular dysfunction, as well as histologic and mitochon…”
BackgroundSelf-citationChanging Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity
Shelburne, N., Simonds, N. I., Adhikari, B. B., Alley, M. C., Desvigne-Nickens, P. M., Dimond, E. P., Filipski, K. K., Gallicchio, L. M., & Minasian, L. M. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0751-0 · Cited by 28
Davaapil, H., Shetty, D. K., & Sinha, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.550504 · Cited by 28
“Studies using VSMCs alone have conflicting reports on the effect of flow on VSMC phenotype (Papadaki et al., 1996; Ueba et al., 1997; Haga et al., 2007; Shi et al., 2010), possibly due to varied forces and culture conditions.”
Narkar, A., Willard, J. M., & Blinova, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063199 · Cited by 33
“[28] investigated the cardiotoxicity of 21 FDAapproved TKIs using patient-specific hiPSC-CMs, reprogrammed in the lab using published protocols from 11 healthy individuals and 2 patients receiving TKI cancer treatment.”
MethodTissue-engineered heart chambers as a platform technology for drug discovery and disease modeling
Mousavi, A., Stefanek, E., Jafari, A., Ajji, Z., Naghieh, S., Akbari, M., & Savoji, H. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.212916 · Cited by 29
Humanity in a Dish: Population Genetics with iPSCs
Warren, C. R., & Cowan, C. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.09.006 · Cited by 27
Hanousková, B., Skála, M., Brynychová, V., Zárybnický, T., Skarková, V., Kazimírová, P., Vernerová, A., Souček, P., Skálová, L., Pudil, R., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108883 · Cited by 27
Cell reprogramming: methods, mechanisms and applications
Zhu, F., & Nie, G. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00229-x · Cited by 28
“In another study, Sharma and co-workers utilized human iPSCs–derived cardiomyocytes, endothelial cells or cardiac fibroblasts to systematically evaluate cell type–specific cardiotoxicities of tyrosine kinase inhibitors (Sharma et al. 2017).”
Bersell, K. R., Yang, T., Mosley, J. D., Glazer, A. M., Hale, A. T., Kryshtal, D. O., Kim, K., Steimle, J. D., Brown, J. D., Salem, J., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.062193 · Cited by 26
Cardiac macrotissues-on-a-plate models for phenotypic drug screens
Meyer, T., Tiburcy, M., & Zimmermann, W. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.03.002 · Cited by 32
Genova, E. C., Cavion, F., Lucafò, M., Leo, L. D., Pelin, M., Stocco, G., & Decorti, G. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i12.1020 · Cited by 29
Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?
Bruyneel, A. A. N., McKeithan, W. L., Feyen, D. A. M., & Mercola, M. A. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.003 · Cited by 27
Self-citationChristidi, E., Huang, H., & Brunham, L. R. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.06.002 · Cited by 26
Conway, M. K., Xu, T., Kirkpatrick, A., Ripp, S. A., Sayler, G. S., & Close, D. M. (2020) · BMC Biology · doi:10.1186/s12915-020-00815-2 · Cited by 24
Luo, Y., Zhang, M., Chen, Y., Chen, Y., & Zhu, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.720099 · Cited by 28
Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Hnatiuk, A. P., Bruyneel, A. A. N., Tailor, D., Pandrala, M., Dheeraj, A., Li, W., Serrano, R., Feyen, D. A. M., Vu, M. M., Amatya, P. L., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3652 · Cited by 24
“We have shown previously that BCR-ABL and other kinase inhibitor drugs impair hiPSC-CMs contractility, indicating a direct detrimental effect on cardiomyocytes (33).”
Self-citationButel-Simoes, L. E., Haw, T. J., Williams, T. D., Sritharan, S., Gadre, P., Herrmann, S. M., Herrmann, J., Ngo, D. T. M., & Sverdlov, A. L. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.17947 · Cited by 24
Arzt, M., Gao, B., Mozneb, M., Pohlman, S., Cejas, R. B., Liu, Q., Huang, F., Yu, C., Zhang, Y., Fan, X., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.08.005 · Cited by 23
“To determine the cardiotoxic impact of SPEDOX-6 on other cardiovascular cell types, we subjected hiPSC-ECs and hiPSC-CFs to SPEDOX-6 and UF DOX (Figure 4). hiPSC-CMs typically show limited proliferation after day 30 of differentiation, unless subjected to exogenous stimulation (Sharma et al., 2017).”
BackgroundMethodInfluentialSelf-citationSong, L., Ahmed, M. F., Li, Y., Bejoy, J., Zeng, C., & Li, Y. (2017) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2017.0307 · Cited by 23
“10 Heparin microparticles allowed the delivery of heparin-bounding growth factors BMP-2, vascular endothelial growth factor, and fibroblast growth factor-2, 49 which stimulated the alkaline phosphatase activity of skeletal myoblasts and increased the DNA content mediated by cell particle contact.”
Yang, B., & Papoian, T. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3584 · Cited by 23
“Thus, hiPSC‐CMs can be used to screen for cardiovascular toxicities associated with anticancer TKIs and the results correlated with clinical phenotypes (Sharma et al., 2017).”
MethodResultThe Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development
Zhou, Z., Zhu, J., Jiang, M., Sang, L., Hao, K., & He, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050704 · Cited by 23
“With human-induced pluripotent stem cell-cardiomyocytes (hiPSC-CMs) derived from healthy people or patients, Arun et al. proposed the heart safety index to evaluate drug-induced cardiotoxicity with tyrosine kinase inhibitor (TKI) approved by the US Food and Drug Administration (FDA) [43].”
BackgroundInfluentialDesigning Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety
Pandrala, M., Bruyneel, A. A. N., Hnatiuk, A. P., Mercola, M. A., & Malhotra, S. V. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01853 · Cited by 25
Self-citationReduced Cardiotoxicity of Ponatinib-Loaded PLGA-PEG-PLGA Nanoparticles in Zebrafish Xenograft Model
Al-Thani, H. F., Shurbaji, S., Zakaria, Z. Z., Hasan, M. H., Goračinova, K., Korashy, H. M., & Yalcin, H. C. (2022) · Materials · doi:10.3390/ma15113960 · Cited by 22
“The dosing rationale that was tested for Ponatinib was based on the literature [47].”
BackgroundLiu, S., Fang, C., Zhong, C., Li, J., & Xiao, Q. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09835-4 · Cited by 22
“By utilizing this novel platform, they found that VEGFR2/PDGFR-inhibiting TKIs caused cardiotoxicity in hiPSC-CMs as well as in ECs and CFs derived from hiPSCs, reflecting their cardiotoxicity in patients(Sharma et al. 2017).”
BackgroundCardiotoxicity associated with tyrosine kinase-targeted anticancer therapy
Lee, W. S., & Kim, J. (2018) · Molecular & Cellular Toxicology · doi:10.1007/s13273-018-0027-z · Cited by 23
Greenberg, M. J., Daily, N., Wang, A., Conway, M. K., & Wakatsuki, T. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00120 · Cited by 24
“This missed cardiotoxicity is one of the reasons that drugs designed based on mouse studies fail in clinical trials (65, 66).”
BackgroundGustafson, D., Fish, J. E., Lipton, J. H., & Aghel, N. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00560-x · Cited by 21
Goßmann, M., Linder, P., Thomas, U., Juhász, K., Lemme, M., George, M., Fertig, N., Dragicevic, E., & Stoelzle‐Feix, S. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106892 · Cited by 21
Cardiovascular microphysiological systems (CVMPS) for safety studies – a pharma perspective
Pointon, A., Maher, J. M., Davis, M., Baker, T. K., Cichocki, J. A., Ramsden, D., Hale, C. M., Kolaja, K. L., Lévesque, P., Sura, R., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc01040e · Cited by 22
Assessing cardiac safety in oncology drug development
Seltzer, J. H., Gintant, G. A., Amiri‐Kordestani, L., Singer, J. W., Koplowitz, L. P., Moslehi, J. J., Barac, A., & Yu, A. F. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.04.010 · Cited by 21
“In addition, preclinical models may be useful to dissect mechanisms of toxicities for existing cancer drugs.(25) Phenotypic screens are used in early drug discovery efforts to identify and avoid potential safety hazards, as it is often difficult to determine the (multiple) mechanisms involved in various cardiotoxi-”
BackgroundSelf-citationAltrocchi, C., Ammel, K. V., Steemans, M., Kreir, M., Tekle, F. B., Teisman, A. C. H., Gallacher, D. J., & Lu, H. R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1229960 · Cited by 24
Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic?
Balachandran, L., Haw, T. J., Leong, A. J. W., Croft, A. J., Chen, D., Kelly, C., Sverdlov, A. L., & Ngo, D. T. M. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.01.013 · Cited by 20
Kadowaki, H., Akazawa, H., Ishida, J., & Komuro, I. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0467 · Cited by 21
Stem Cell Based Preclinical Drug Development and Toxicity Prediction
Kumar, D., Baligar, P., Srivastav, R., Narad, P., Raj, S., Tandon, C., & Tandon, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201019104712 · Cited by 21
Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity
Tu, C., Cunningham, N. J., Zhang, M., & Wu, J. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.613837 · Cited by 21
“In fact, several studies have employed high-throughput platforms to investigate druginduced vascular toxicity or to identify therapeutic agents using iPSC-ECs (Iwata et al., 2017; Sharma et al., 2017) or iPSC-SMCs (Zhang et al.”
BackgroundSelf-citationOrgan-on-a-chip and 3D printing as preclinical models for medical research and practice
Jain, A., Mathur, T., Pandian, N. K. R., & Selahi, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819178-1.00009-5 · Cited by 26
Atrial-specific hiPSC-derived cardiomyocytes in drug discovery and disease modeling
Gharanei, M., Shafaattalab, S., Sangha, S. S., Gunawan, M. G., Laksman, Z., Hove‐Madsen, L., & Tibbits, G. F. (2021) · Methods · doi:10.1016/j.ymeth.2021.06.009 · Cited by 21
Daley, M. C. (2022) · ALTEX · doi:10.14573/altex.2109131 · Cited by 24
“For tyrosine kinase inhibitors, a subset of anti-cancer therapeutics with wide-ranging cardiovascular side effects, prioritization further discerns between inhibitor sub-classes (Sharma et al., 2017).”
BackgroundInfluentialOrganoidChip facilitates hydrogel-free immobilization for fast and blur-free imaging of organoids
Moshksayan, K., Harihara, A., Mondal, S., Hegarty, E., Atherly, T. A., Sahoo, D. K., Jergens, A. E., Mochel, J. P., Allenspach, K., Zoldan, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38212-8 · Cited by 20
Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors
Travers, R. J., Stepanian, A., & Jaffe, I. Z. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.319864 · Cited by 19
“99 These preclinical studies suggest that BTKIs are directly toxic to ECs in vitro and, as with other classes of KIs, 31,100 the degree of EC toxicity correlates with the relative clinical cardiovascular toxicity.”
Modern concepts in cardio-oncology
Rassaf, T., & Totzeck, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.110 · Cited by 19
Shen, L., Li, C., Zhang, H., Qiu, S., Fu, T., & Xu, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00914 · Cited by 19
Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers
Feng, W., Pourrier, M., Strauss, D. G., Stockbridge, N., & Pang, L. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa010 · Cited by 20
Li, C., Zou, R., Zhang, H., Wang, Y., Qiu, B., Qiu, S., Wang, W., & Xu, Y. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02448-z · Cited by 19
Kalra, R. S., Dhanjal, J. K., Das, M., Singh, B., & Naithani, R. (2021) · Cells · doi:10.3390/cells10102558 · Cited by 21
Chen, Y., Masbuchin, A. N., Fang, Y., Hsu, L.-W., Wu, S., Yen, C., Liu, Y.-W., Hsiao, Y., Wang, J., Rohman, M. S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113962 · Cited by 18
Self-citationCui, X., Sun, J., Li, C., Qiu, S., Shi, C., Ma, J., & Xu, Y. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.06.001 · Cited by 18
Genome-wide off-targets of drugs: risks and opportunities
Giri, A. K., Ianevski, A., & Aittokallio, T. A. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09491-7 · Cited by 18
“…model systems, such as those based on human cardiomyocytes and hepatocytes derived from embryonic stem cells or induced pluripotent stem cells (iPSCs), have been investigated for cardiotoxicity and hepatotoxicity profiling as an alternative to animal models (Grimm et al. 2015; Sharma et al. 2017).”
BackgroundTwo decades of induced pluripotent stem cell research: From discovery to diverse applications
Yamanaka, S. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.02.003 · Cited by 21
Farbehi, N., Neavin, D. R., Cuomo, A. S. E., Studer, L., MacArthur, D. G., & Powell, J. E. (2024) · Nature Genetics · doi:10.1038/s41588-024-01731-9 · Cited by 17
“Specifically, such models could aid in determining appropriate therapeutic ranges and biomarkers to stratify patients who may experience an adverse effect or identify those unlikely to respond to a given drug.”
Ford, L. C., Lin, H., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Human Genomics · doi:10.1186/s40246-024-00665-x · Cited by 20
Apáti, Á., Varga, N., Berecz, T., Erdei, Z., Homolya, L., & Sarkadi, B. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1558207 · Cited by 19
“doxorubicin, sorafenib) are also in the focus of these studies [81].”
BackgroundAssessment of Cardiotoxicity With Stem Cell-based Strategies
Stoter, A. M. S., Hirt, M. N., Stenzig, J., & Weinberger, F. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.08.012 · Cited by 18
OptoDyCE-plate as an affordable high throughput imager for all optical cardiac electrophysiology
Heinson, Y. W., Han, J., & Entcheva, E. G. (2023) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2023.100054 · Cited by 17
“In the presented OptoDyCE-plate system, optogenetic pacing (global and point-pacing) adds an important feature compared to other systems for optical recordings of spontaneous activity [7,20,54], namely control over rate to better quantify drug responses.”
Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches
Rasooly, D., Pereira, A. C., & Joseph, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062703 · Cited by 17
Acquired long QT syndrome and phosphoinositide 3-kinase
Cohen, I. S., Lin, R. Z., & Ballou, L. M. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.05.005 · Cited by 16
Yu, M. S., Spiering, S., & Colas, A. R. (2018) · Journal of Visualized Experiments · doi:10.3791/57688 · Cited by 17
Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development
Lin, X., Tang, J., & Lou, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060525 · Cited by 18
“In addition, the use of patient-specific hiPSCs for CTID can also identify at-risk populations, simulate clinical trials of toxic drugs [157], and identify the toxicity of drugs [158].”
BackgroundReprogramming iPSCs to study age-related diseases: Models, therapeutics, and clinical trials
Esteves, F., Brito, D. V. C., Rajado, A. T., Silva, N., Apolónio, J. D., Roberto, V. P., Araújo, I. M., Nóbrega, C., Castelo‐Branco, P., Bragança, J., et al. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111854 · Cited by 18
Metadata
- Authors
- Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., Matsa, E., Zhang, Y., Kumar, A., Fan, A. C., del Álamo, J. C., Wu, S. M., Moslehi, J. J., Mercola, M., & Wu, J. C.
- Affiliations
- Stanford Medicine (US)
- Northwestern University (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of California San Diego (US)
- Department of Mechanical and Aerospace Engineering, University of California, San Diego, La Jolla, CA 92092, USA.
- Vanderbilt-Ingram Cancer Center (US)
- Corresponding author
- Sharma, Arun
- Burridge, Paul W.
- Wu, Joseph C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-15
- Volume
- 9
- Issue
- 377
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5409837
- OpenAlex
- W2587938050
- Cited by
- 404
- References
- 49
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 55 · 2023: 34 · 2022: 41 · 2021: 50 · 2020: 56 · 2019: 52 · 2018: 47 · 2017: 23
- FWCI
- 37.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (award280979)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- tyrosine kinase inhibitors, cardiotoxicity, human induced pluripotent stem cell-derived cardiomyocytes, high-throughput screening, VEGFR-2 inhibitors, PDGFR inhibitors, endothelial cells, cardiac fibroblasts, insulin signaling, IGF-1 signaling, cardioprotection
- MeSH terms
- Fibroblasts, Humans, Insulin, Insulin-Like Growth Factor I, Models, Biological, Phosphorylation, Sarcomeres, Signal Transduction, Biomarkers, Myocytes, Cardiac, Vascular Endothelial Growth Factor Receptor-2, Protein Kinase Inhibitors, Induced Pluripotent Stem Cells, High-Throughput Screening Assays, Cardiotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.